Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec in Idiopathic Hypereosinophilic Syndrome (HES)
NCT00230334Phase 2Terminated
- Start
- Jun 2003
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in idiopathic hypereosinophilic syndrome (HES). Started Jun 2003; status: terminated.
02
Drugs
03
Conditions
idiopathic hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT00230334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230334.